论文部分内容阅读
■一方是广州威尔曼药业,另一方是白云山科技等11家国内药企;■双方因一种“复合药”是否有专利产生纠纷;■这场纠纷从最初的“剑拔弩张”,到目前正通过协商和解,出现了转机。侵权案硝烟四处起寻和解说法两相异这是一场令全国制药界都十分关注的专利纠纷。一方是专利现在的持有
■ One is Guangzhou Wellman Pharmaceutical and the other is 11 domestic pharmaceutical companies such as Baiyunshan Science and Technology; ■ Both parties have disputes over whether a compound drug has a patent or not; ■ The dispute begins with the initial “tense” There is a turning point right now through reconciliation. This is a patent dispute that has drawn great concern to the pharmaceutical industry in the country. One is holding the patent right now